Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The Role of Multidimensional Prognostic Index to Identify Hospitalized Older Adults with COVID-19 Who Can Benefit from Remdesivir Treatment: An Observational, Prospective, Multicenter Study

C. Custodero, N. Veronese, E. Topinkova, H. Michalkova, MC. Polidori, A. Cella, AJ. Cruz-Jentoft, CAF. von Arnim, M. Azzini, H. Gruner, A. Castagna, G. Cenderello, R. Custureri, T. Zieschang, A. Padovani, E. Sanchez-Garcia, A. Pilotto, Study...

. 2023 ; 40 (7) : 643-651. [pub] 20230613

Language English Country New Zealand

Document type Observational Study, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK ProQuest Central from 2008-06-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 2008-06-01 to 1 year ago
Health & Medicine (ProQuest) from 2008-06-01 to 1 year ago
Psychology Database (ProQuest) from 2008-06-01 to 1 year ago

BACKGROUND: Data regarding the importance of multidimensional frailty to guide clinical decision making for remdesivir use in older patients with coronavirus disease 2019 (COVID-19) are largely unexplored. OBJECTIVE: The aim of this research was to evaluate if the Multidimensional Prognostic Index (MPI), a multidimensional frailty tool based on the Comprehensive Geriatric Assessment (CGA), may help physicians in identifying older hospitalized patients affected by COVID-19 who might benefit from the use of remdesivir. METHODS: This was a multicenter, prospective study of older adults hospitalized for COVID-19 in 10 European hospitals, followed-up for 90 days after hospital discharge. A standardized CGA was performed at hospital admission and the MPI was calculated, with a final score ranging between 0 (lowest mortality risk) and 1 (highest mortality risk). We assessed survival with Cox regression, and the impact of remdesivir on mortality (overall and in hospital) with propensity score analysis, stratified by MPI = 0.50. RESULTS: Among 496 older adults hospitalized for COVID-19 (mean age 80 years, female 59.9%), 140 (28.2% of patients) were treated with remdesivir. During the 90 days of follow-up, 175 deaths were reported, 115 in hospital. Remdesivir treatment significantly reduced the risk of overall mortality (hazard ratio [HR] 0.54, 95% confidence interval CI 0.35-0.83 in the propensity score analysis) in the sample as whole. Stratifying the population, based on MPI score, the effect was observed only in less frail participants (HR 0.47, 95% CI 0.22-0.96 in propensity score analysis), but not in frailer subjects. In-hospital mortality was not influenced by remdesivir use. CONCLUSIONS: MPI could help to identify less frail older adults hospitalized for COVID-19 who could benefit more from remdesivir treatment in terms of long-term survival.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010870
003      
CZ-PrNML
005      
20230801132650.0
007      
ta
008      
230718s2023 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40266-023-01036-2 $2 doi
035    __
$a (PubMed)37310575
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Custodero, Carlo $u Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy
245    14
$a The Role of Multidimensional Prognostic Index to Identify Hospitalized Older Adults with COVID-19 Who Can Benefit from Remdesivir Treatment: An Observational, Prospective, Multicenter Study / $c C. Custodero, N. Veronese, E. Topinkova, H. Michalkova, MC. Polidori, A. Cella, AJ. Cruz-Jentoft, CAF. von Arnim, M. Azzini, H. Gruner, A. Castagna, G. Cenderello, R. Custureri, T. Zieschang, A. Padovani, E. Sanchez-Garcia, A. Pilotto, Study Group Investigators
520    9_
$a BACKGROUND: Data regarding the importance of multidimensional frailty to guide clinical decision making for remdesivir use in older patients with coronavirus disease 2019 (COVID-19) are largely unexplored. OBJECTIVE: The aim of this research was to evaluate if the Multidimensional Prognostic Index (MPI), a multidimensional frailty tool based on the Comprehensive Geriatric Assessment (CGA), may help physicians in identifying older hospitalized patients affected by COVID-19 who might benefit from the use of remdesivir. METHODS: This was a multicenter, prospective study of older adults hospitalized for COVID-19 in 10 European hospitals, followed-up for 90 days after hospital discharge. A standardized CGA was performed at hospital admission and the MPI was calculated, with a final score ranging between 0 (lowest mortality risk) and 1 (highest mortality risk). We assessed survival with Cox regression, and the impact of remdesivir on mortality (overall and in hospital) with propensity score analysis, stratified by MPI = 0.50. RESULTS: Among 496 older adults hospitalized for COVID-19 (mean age 80 years, female 59.9%), 140 (28.2% of patients) were treated with remdesivir. During the 90 days of follow-up, 175 deaths were reported, 115 in hospital. Remdesivir treatment significantly reduced the risk of overall mortality (hazard ratio [HR] 0.54, 95% confidence interval CI 0.35-0.83 in the propensity score analysis) in the sample as whole. Stratifying the population, based on MPI score, the effect was observed only in less frail participants (HR 0.47, 95% CI 0.22-0.96 in propensity score analysis), but not in frailer subjects. In-hospital mortality was not influenced by remdesivir use. CONCLUSIONS: MPI could help to identify less frail older adults hospitalized for COVID-19 who could benefit more from remdesivir treatment in terms of long-term survival.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a prospektivní studie $7 D011446
650    12
$a křehkost $x farmakoterapie $7 D000073496
650    _2
$a prognóza $7 D011379
650    12
$a COVID-19 $7 D000086382
650    _2
$a farmakoterapie COVID-19 $7 D000093485
650    _2
$a geriatrické hodnocení $x metody $7 D015577
655    _2
$a pozorovací studie $7 D064888
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Veronese, Nicola $u Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, via del Vespro, 141, 90127, Palermo, Italy. nicola.veronese@unipa.it $1 https://orcid.org/000000029328289X
700    1_
$a Topinkova, Eva $u Department of Geriatrics, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Faculty of Health and Social Sciences, University of South Bohemia, Ceske Budejovice, Czech Republic
700    1_
$a Michalkova, Helena $u Department of Geriatrics, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Faculty of Health and Social Sciences, University of South Bohemia, Ceske Budejovice, Czech Republic
700    1_
$a Polidori, Maria Cristina $u Ageing Clinical Research, Department II of Internal Medicine and Center for Molecular Medicine, University of Cologne, Cologne, Germany
700    1_
$a Cella, Alberto $u Department of Geriatric Care, Orthogeriatrics and Rehabilitation, Galliera Hospital, Genoa, Italy
700    1_
$a Cruz-Jentoft, Alfonso J $u Servicio de Geriatría, Hospital Universitario Ramón y Cajal, (IRYCIS), Madrid, Spain
700    1_
$a von Arnim, Christine A F $u Division of Geriatrics, University Medical Center Goettingen, Goettingen, Germany
700    1_
$a Azzini, Margherita $u Geriatrics Unit, "Mater Salutis" Hospital, Legnago ULSS 9 Scaligera, Verona, Italy
700    1_
$a Gruner, Heidi $u Serviço de Medicina Interna, Hospital Curry Cabral, Centro Hospitalar Universitário Lisboa Central/Universidade Nova de Lisboa, Lisbon, Portugal
700    1_
$a Castagna, Alberto $u Geriatrics Unit, "Pugliese Ciaccio" Hospital, Catanzaro, Italy
700    1_
$a Cenderello, Giovanni $u Infectious Disease Unit, Sanremo Hospital, ASL 1 Imperiese, Sanremo, Italy
700    1_
$a Custureri, Romina $u Department of Geriatric Care, Orthogeriatrics and Rehabilitation, Galliera Hospital, Genoa, Italy
700    1_
$a Zieschang, Tania $u Klinikum Oldenburg AöR, Oldenburg University, Oldenburg, Germany
700    1_
$a Padovani, Alessandro $u Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
700    1_
$a Sanchez-Garcia, Elisabet $u Servicio de Geriatría, Hospital Universitario Ramón y Cajal, (IRYCIS), Madrid, Spain
700    1_
$a Pilotto, Alberto $u Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy $u Department of Geriatric Care, Orthogeriatrics and Rehabilitation, Galliera Hospital, Genoa, Italy
710    2_
$a Study Group Investigators
773    0_
$w MED00001454 $t Drugs & aging $x 1179-1969 $g Roč. 40, č. 7 (2023), s. 643-651
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37310575 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132646 $b ABA008
999    __
$a ok $b bmc $g 1963341 $s 1197135
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 40 $c 7 $d 643-651 $e 20230613 $i 1179-1969 $m Drugs &aging $n Drugs Aging $x MED00001454
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...